Browse press releases
The newest releases come first, each with its full text here and a link to its original. Try the filters to narrow them down.
- United Arab Emirates Medical Semiconductor Memory Market Size, Share, Trends, and Forecast to 2032 | Digital Health, Medical Imaging, and Remote Monitoring Fuel GrowthUnlock UAE medical memory opportunities with insights into demand, competition, market entry strategies, key applications, technologies, and distributors
- Poland Medical Semiconductor Memory Market Size, Trends and Forecast to 2032 | Digital Health, Connected Care, and Next-generation Memory Open Strategic Growth OpportunitiesPinpoint high-potential memory types and medical applications using demand trends, competitive positioning, distributor insights and market-entry analysis in Poland
- After Historic FDA Hearing On Psychedelic Therapies, Grassroots Student Group Mobilizes To Shape What Comes NextSeptember 29, 2026 – WASHINGTON, D.C. — On September 14th, 2026 the U.S. Food and Drug Administration (FDA) held a public hearing on “Considerations for Potential Future Therapeutic Use of Psychedelic Drugs.” Two weeks later, the hearing is over – but the opportunity for the public to help shape the federal conversation is not. […]
- DeloitteDeloitte Model Explores $527 Billion Growth Opportunity in US Women's Health Through Health Promotion, Prevention and Early DetectionProactive, life-stage-aware care could improve outcomes, reduce downstream costs and may support a modeled health span increase of up to 20 years — Key takeaways Prevention could expand health span: Under a prevention and improved disease-management...
- AMRYTT MEDIAInternational Plus Publishes the Protocol Governing Where AI Is Used in Its International Patient PathwayInternational Plus, a Turkish dental group authorised by the Turkish Ministry of Health, has published the internal protocol that defines where artificial intelligence is applied in its international patient pathway and, equally, where clinical decisions remain with named specialists. The document follows a health innovation panel at Atlas University in Istanbul at which chief executive Mehmet Ali Arici set out the group's position on AI...
- AB Science provides an update on its development plan and financial calendar following a sponsor Good Clinical Practice inspectionPRESS RELEASE
- Havas Health NetworkMeet Jordic: The Unlikely Voice of a Heart-Health Warning Men Need to HearLaunching today on World Heart Day, JOE Media Group's 'Listen to Jordic' turns a commonly ignored symptom into a captivating folk anthem about cardiovascular risk. — What if an early warning sign of heart disease was not in your chest, but in your...
- iRegene therapeuticsiRegene Therapeutics's NouvSight001 Cleared for Clinical Trials in the U.S. and China for Retinitis Pigmentosa- Following its Parkinson's disease program, iRegene advances another off-the-shelf cell therapy into clinical development in the — iRegene Therapeutics Co., Ltd. ("iRegene" or the "Company"), a biotechnology company pioneering...
- Hengrui PharmaHengrui Pharma and Novo Enter Exclusive License Agreement for Once-Weekly Oral GLP-1/GIP Dual Receptor Agonist HRS-1596HRS-1596 is a phase I-ready GLP-1/GIP dual receptor agonist for once-weekly oral dosing Total potential deal value is up to 2.6 billion US dollars, including 300 million dollars upfront, as well as potential sales royalties SHANGHAI, Sept. 29, 2026 -- Hengrui Pharma...
- NewGenIVF Group LimitedNewGen Announces Pricing of $1.25 Million Public OfferingNewGenIvf Group Limited (NASDAQ: NIVF) (the “Company”), a tech-forward, diversified, multi-jurisdictional high-growth entity transforming industries through innovative solutions across real estate development, digital asset management and reproductive health solutions, today announced the pricing of a public offering made on a reasonable best efforts basis with gross proceeds to the Company expected to be approximately $1.25 million, before deducting placement agent fees and other offering expenses payable by the Company.
- Evosep and Mass Dynamics Join Forces to Standardize Proteomics Sample Preparation for PharmaEvosep and Mass Dynamics partner to standardize proteomics workflows, combining automated sample prep, QC, and analytics for pharma.
- 和黄医药(00013.HK)宣布提交沃瑞沙 (ORPATHYS) 联合泰瑞沙(TAGRISSO)用于治疗MET驱动的EGFR突变肺癌的美国新药上市申请格隆汇9月29日丨和黄医药(00013.HK)宣布阿斯利康已向美国食品药品监督管理局(“FDA”)提交沃瑞沙(ORPATHYS，赛沃替尼/savolitinib)和泰瑞沙(TAGRISSO，奥希替尼/osimertinib)的联合疗法的新药上市申请，用于治疗接受一种表皮生长因子受体(“EGFR”)酪氨酸激酶抑制剂(“TKI”)治疗期间或之后出现疾病进展的伴有MET过表达或扩增的局部晚期或转移性非小...